Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Vaillant

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
The Lancet. Gastroenterology & Hepatology|October 2, 2017
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Victor Pântea, Valentin Cebotarescu, et al.
Hepatology Communications|April 3, 2022
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infectionMichel Bazinet, Mark Anderson, Victor Pântea, et al.
Hepatology Communications|September 24, 2021
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based TherapyMichel Bazinet, Mark Anderson, Victor Pântea, et al.
Journal of Hepatology|November 8, 2025
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access programChristiane Stern, Véronique Loustaud-Ratti, Cihan Yurdaydin, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
The Lancet. Gastroenterology & Hepatology|October 2, 2017
Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trialMichel Bazinet, Victor Pântea, Valentin Cebotarescu, et al.
Hepatology Communications|April 3, 2022
HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infectionMichel Bazinet, Mark Anderson, Victor Pântea, et al.
Hepatology Communications|September 24, 2021
Analysis of HBsAg Immunocomplexes and cccDNA Activity During and Persisting After NAP-Based TherapyMichel Bazinet, Mark Anderson, Victor Pântea, et al.
Journal of Hepatology|November 8, 2025
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access programChristiane Stern, Véronique Loustaud-Ratti, Cihan Yurdaydin, et al.
Pageof 6